High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2022

High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists

Résumé

The past fifty years have been marked by the surge of neurodegenerative diseases. Unfortunately, current treatments are only symptomatic. Hence, the search for new and innovative therapeutic targets for curative treatments becomes a major challenge. Among these targets, the adenosine A2A receptor (A2AAR) has been the subject of much research in recent years. In this paper, we report the design, synthesis and pharmacological analysis of quinazoline derivatives as A2AAR antagonists with high ligand efficiency. This class of molecules has been discovered by a virtual screening and bears no structural semblance with reference antagonist ZM-241385. More precisely, we identified a series of 2-aminoquinazoline as promising A2AAR antagonists. Among them, one compound showed a high affinity towards A2AAR (21a, Ki = 20 nM). We crystallized this ligand in complex with A2AAR, confirming one of our predicted docking poses and opening up possibilities for further optimization to derive selective ligands for specific adenosine receptor subtypes.

Dates et versions

hal-04402301 , version 1 (18-01-2024)

Identifiants

Citer

Raphaël Bolteau, Romain Duroux, Amelie Laversin, Brandon Vreulz, Anna Shiriaeva, et al.. High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists. European Journal of Medicinal Chemistry, 2022, European Journal of Medicinal Chemistry, 241 (5), pp.114620. ⟨10.1016/j.ejmech.2022.114620⟩. ⟨hal-04402301⟩

Collections

RIIP UNIV-LILLE
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More